The Nasdaq 100 closed higher by over 100 points on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform.

Bristol-Myers Squibb

• The Trade: Bristol-Myers Squibb Company (NYSE:BMY) EVP, Chief Human Resources Ann Powell sold a total of 17,986 shares at an average price of $61.25. The insider received around $1.1 million from selling those shares.
• What’s Happening: The FDA approved Bristol Myers Squibb's Reblozyl for initial anemia treatment in low- to intermediate-risk myelodysplastic syndromes.
• What Bristol-Myers Squibb Does: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders.

Have a look at our premarket coverage here

Schlumberger

• The Trade: Schlumberger Limited (NYSE:SLB) EVP & CFO Stephane Biguet sold a total of 6,250 shares at an average price of $56.85. The insider received around $355,313 from selling those shares.
• What’s Happening: Schlumberger bagged a five-year contract from Petrobras to deploy their Delfi digital platform across the enterprise.
• What SLB Does: SLB, formerly known as Schlumberger, is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions.

Coinbase Global

Andersons

Check This Out: Top 3 Materials Stocks That May Implode This Month